« Back to Record
Citation APA

Limentani, S. S., Disis, M., Awada, A., Berlière, M., Amant, F., Levine, E., Burny, W., Callegaro, A., De Sousa Alves, P. M., Louahed, J., Brichard, V., Csampone, M., Lehmann, F., Dorval, T., Curigliano, G., de Boer, R., Vogel, C., White, S., Bachelot, T., & Canon, J.-L. (2016). A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast cancer research and treatment, 156(2), 319-330. doi:10.1007/s10549-016-3751-x


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/247839

Limentani, S. S., Disis, M., Awada, A., Berlière, M., Amant, F., Levine, E., Burny, W., Callegaro, A., De Sousa Alves, P. M., Louahed, J., Brichard, V., Csampone, M., Lehmann, F., Dorval, T., Curigliano, G., de Boer, R., Vogel, C., White, S., Bachelot, T., & Canon, J.-L. (2016). A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast cancer research and treatment, 156(2), 319-330. doi:10.1007/s10549-016-3751-x